Anticoagulation & thrombolysis in critical care
Bedside summary
Heparins: UFH (titratable, APTT-monitored, reversible with protamine — the ICU choice in renal failure/bleeding risk), LMWH (predictable, anti-Xa monitoring in renal failure/extremes of weight). Citrate for circuit anticoagulation in CRRT. Direct agents (dabigatran/rivaroxaban etc.) — know the reversal (idarucizumab; andexanet/PCC). Thrombolytics (alteplase/tenecteplase) for STEMI without PCI access, massive PE with shock, and selected stroke.
Red flags
- Falling platelets on heparin is HIT until scored otherwise — thrombosis, not bleeding, is its killer
- Thrombolysis contraindications are relative when the alternative is death — senior decision, documented
Management
- Every ICU patient gets VTE prophylaxis ASSESSED daily — LMWH unless contraindicated, mechanical if bleeding risk
- HIT: platelets falling >50% at day 5–10 on heparin ± thrombosis — 4T score, STOP all heparin (including flushes), start argatroban/danaparoid, never wait for the assay in high suspicion
- Bleeding on anticoagulation: stop drug, give the antidote (protamine/vitamin K + PCC for warfarin/idarucizumab for dabigatran), local control, and re-plan
- Thrombolysis in arrest for suspected massive PE: give and continue CPR 60–90 min
- Peri-procedure: time neuraxial/line removal to LMWH dosing (12–24 h windows)
Drugs & doses
Prophylaxis for everyone assessed daily; UFH when you need an off-switch; and respect HIT.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.